Safety and Tolerability of Oshadi Icp In Patients With Type 1 Diabetes Mellitus - Phase Ib Clinical Study

Phase 1

Completed

• Conditions: Diabetes Mellitus, Insulin-Dependent, 1
• Interventions: Drug: Oshadi Icp

• Registration Number: NCT01772251
• Lead Sponsor: Oshadi Drug Administration

Brief Summary

Diabetes mellitus (DM) is a chronic disease of carbohydrate, fat, and protein metabolism caused by an absolute or relative deficiency of insulin, an anabolic hormone. The current methods of insulin therapy for diabetic patients are multiple daily injection therapy and continuous subcutaneous insulin infusion with an external pump. This rout of administration may lead to hyperinsulinemia as insulin is administered in a non physiological way, targeting mainly extra hepatic tissues (muscle, fat).

A method of providing insulin without the need for injections has been a goal in drug delivery.

Oshadi Drug Administration Ltd. has developed oral carrier for proteins based on biochemistry and quantum theory of biochemical reactions. The carrier enables the absorption of proteins from the gastrointestinal tract in their full structure. Oshadi has also developed the Oshadi Icp - insulin, proinsulin and C-peptide in Oshadi carrier, administrated orally. This study was design in order to evaluate the safety and feasibility of multiple administration of Oshadi Icp

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2013-01-17
• Study First Submitted QC: 2013-01-18
• Study First Posted: 2013-01-21
• Study Start: 2013-02
• Status Verified: 2013-06
• Primary Completion: 2013-06
• Study Completion: 2013-06
• Last Update Submitted: 2013-10-27
• Last Update Posted: 2013-10-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• Type 1 diabetes mellitus (according to ADA criteria) for more than 1 year.
• Male/female 18 years old and older.
• BMI≥18.5 and ≤25
• Female of childbearing age must commit to avoid pregnancy and use contraception during the study.
• Patients must understand and be willing to give written informed consent prior to any study procedures or evaluations and be willing to adhere to all study schedules and requirements.

Exclusion Criteria

• Any history of significant cardiac, renal, neurologic, metabolic, pulmonary, gastrointestinal, hematologic abnormality, chronic hepatic disease or any other disease which in the judgment of the investigator would interfere with the study or confound the results.
• Symptomatic DKA in the last 6 months
• Patients with positive HIV or HCV serology or positive HBsAg at screening.
• History or evidence of any active liver disease.
• History of epilepsy.
• One hypoglycemic seizure episode in the last six months or more than one hypoglycemic seizure episode in the last year.
• History of sever recurrent hypoglycemic unawareness.
• C-peptide >3 mg/ml (fasting)
• Total average daily insulin dosage ≥1 IU/kg of body weight.
• Polycystic ovary syndrome
• Acanthosis nigricans
• 6.5% > HbA1c or HbA1c >10%
• eGFR<60.
• Female patients who are breastfeeding or have a positive pregnancy test at screening or at any time during the study and not willing to practice birth control during study period.
• Inability to give written informed consent
• History of alcohol or drug abuse within 6 months of screening.
• Patients who have a positive urine drug screen for substances of abuse (benzodiazepine, THC, opiates, amphetamines, cocaine) at the screening.
• Mental disorders.
• Patients with poor venous access
• Significant swallowing disorders
• Digestive disorders
• Small bowel surgery
• Any intercurrent disease during the last week prior to screening which in the judgment of the investigator might affect blood glucose level.
• Any infectious disease developed during the 4 weeks prior to the study.
• Malabsorption disorders.
• Any significant abnormality by principal investigator in the baseline laboratory evaluation: liver and kidney functions, electrolytes, albumin, lipase, TSH, hemoglobin, white blood cell count and differential, platelets.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Oshadi Icp & placebo	Oshadi Icp	-

Primary Outcome Measures

Name	Time	Method
Adverse events and serious adverse events occurence	last follow-up visit (day 23)

Secondary Outcome Measures

Name	Time	Method
• To assess the pharmacodynamic effect of multiple doses of Oshadi Icp as measured by the area under the glucose concentration-time curve	last administration day (day 17)

Trial Locations

Locations (1)

Assaf-Harofeh Medical Center; 🇮🇱 Zerifin, Israel